Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method from the International Immuno-Oncology Biomarkers Working Group: Part 2: TILs in Melanoma, Gastrointestinal Tract Carcinomas, Non–Small Cell Lung Carcinoma and Mesothelioma, Endometrial and Ovarian Carcinomas, Squamous Cell Carcinoma of the Head and Neck, Genitourinary Carcinomas, and Primary Brain Tumors
Shona A. Hendry, Roberto Salgado, Thomas Gevaert et al. · Advances in Anatomic Pathology · 2017
Assessment of the immune response to tumors is growing in importance as the prognostic implications of this response are increasingly recognized, and as immunotherapies are evaluated and implemented in different tumor types. However, many different approaches can be used to assess and describe the immune response, which limits efforts at implementation as a routine clinical biomarker. In part 1 of this review, we have proposed a standardized methodology to assess tumor-infiltrating lymphocytes (TILs) in solid tumors, based on the International Immuno-Oncology Biomarkers Working Group guidelines for invasive breast carcinoma. In part 2 of this review, we discuss the available evidence for the prognostic and predictive value of TILs in common solid tumors, including carcinomas of the lung, gastrointestinal tract, genitourinary system, gynecologic system, and head and neck, as well as primary brain tumors, mesothelioma and melanoma. The particularities and different emphases in TIL assessment in different tumor types are discussed. The standardized methodology we propose can be adapted to different tumor types and may be used as a standard against which other approaches can be compared. Standardization of TIL assessment will help clinicians, researchers and pathologists to conclusively evaluate the utility of this simple biomarker in the current era of immunotherapy.
Cited by 799 works. doi:10.1097/pap.0000000000000161 Open-access PDF
Authors
- Shona A. Hendry
- Roberto Salgado
- Thomas Gevaert
- Prudence Anne Russell
- Bibhusal Thapa
- Michael Christie
- Koen K Van de Vijver
- Monica Valeria Estrada
- Paula I. González Ericsson
- Melinda M. Sanders
- Benjamin Solomon
- Cinzia Solinas
- Gert G. G. M. Van den Eynden
- Yves Allory
- Matthias Preusser
- Johannes Andreas Hainfellner
- Giancarlo Pruneri
- Andrea Vingiani
- Sandra Demaria
References
- PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
- Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
- Global cancer statistics, 2012
- The blockade of immune checkpoints in cancer immunotherapy
- Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer
- Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
- Integrated genomic analyses of ovarian carcinoma
- Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer